Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADVIL CONGESTION RELIEF vs ALAWAY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction
ALAWAY (cetirizine ophthalmic solution) is a selective histamine H1-receptor antagonist that inhibits histamine release from mast cells, reducing ocular itching and allergic conjunctivitis symptoms.
temporary relief of nasal congestion,sinus pressure,headache,fever,minor aches and pains associated with common cold or flu
Treatment of ocular itching associated with allergic conjunctivitis
1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.
2 doses (each dose = 2 sprays) per nostril, repeated every 12 hours as needed. Each spray delivers 50 mg of sodium cromoglicate. Route: intranasal. Maximum: 2 doses per nostril per day.
Ibuprofen: 2-4 hours (short half-life requires frequent dosing). Pseudoephedrine: 5-8 hours (longer in alkaline urine). Context: Half-life prolonged in renal impairment.
Terminal elimination half-life of 3-4 hours in healthy adults; extended to 10-15 hours in severe renal impairment (Cr Cl <30 m L/min). Clinical context: Twice-daily dosing is standard; dose adjustment required in renal insufficiency.
ibuprofen: primarily hepatic via CYP2C9; phenylephrine: primarily hepatic via monoamine oxidase (MAO) and sulfation
Not extensively metabolized in the eye; systemic metabolism by hepatic CYP450 enzymes is minimal due to low systemic absorption.
Renal: ~90% as unchanged drug and metabolites (ibuprofen: <10% unchanged, pseudoephedrine: 43-96% unchanged). Biliary/fecal: minimal (<5%).
Primarily renal excretion (80-90% unchanged drug) via glomerular filtration and active tubular secretion; 10-20% fecal excretion. Minimal biliary elimination.
Ibuprofen: >99% bound to albumin. Pseudoephedrine: 20-30% bound to albumin.
Approximately 65-75% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Ibuprofen: 0.1-0.2 L/kg (low, reflects high protein binding). Pseudoephedrine: 2.6-3.5 L/kg (extensive tissue distribution).
Vd: 1.0-1.5 L/kg, indicating extensive distribution into total body water and tissues; high penetration into ocular tissues and respiratory mucosa.
Oral: Ibuprofen ~80-100% (high), Pseudoephedrine ~100% (high).
Oral: ~50% due to first-pass metabolism (CYP3A4 and P-glycoprotein). Ophthalmic solution: negligible systemic absorption (<0.5% of topical dose). Intravenous: 100%.
Avoid use if Cr Cl <30 m L/min. For Cr Cl 30-59 m L/min, use lowest effective dose and shortest duration.
No dosage adjustment required. Sodium cromoglicate is primarily excreted unchanged in urine, but no specific GFR-based adjustments are recommended due to wide safety margin.
Avoid use in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), use with caution and at the lowest effective dose.
No dosage adjustment required. Sodium cromoglicate is minimally metabolized and undergoes biliary excretion; however, no specific Child-Pugh based modifications are established.
Not recommended in children under 12 years of age due to phenylephrine component. For children 12 years and older, same as adult dosing.
Children 2-5 years: 1 spray per nostril every 6-8 hours as needed. Children 6 years and older: same as adult (2 sprays per nostril every 12 hours). Maximum 2 doses per nostril per day in all age groups. Weight-based dosing not established.
Start at the low end of dosing range; avoid use in patients 65 years and older if possible due to increased risk of adverse effects; if necessary, use lowest effective dose for shortest duration.
No specific dose adjustment required; use same adult dose. Caution in elderly with renal impairment due to potential accumulation, though clinical significance is minimal.
ibuprofen carries a black box warning for increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal, and for serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines
None
cardiovascular risk,gastrointestinal risk,renal effects,avoid concomitant use of other NSAIDs,hypertension,hyperthyroidism,diabetes,heart disease,use with MAOIs may cause hypertensive crisis
For topical ophthalmic use only,Do not inject,Contact lens wearers should remove lenses before instillation and wait at least 10 minutes before reinserting,May cause temporary blurred vision,Avoid touching dropper tip to any surface to prevent contamination
hypersensitivity to ibuprofen, phenylephrine, or any component,history of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs,perioperative pain in setting of coronary artery bypass graft (CABG) surgery,severe hypertension,severe coronary artery disease,use of MAOIs or within 14 days of stopping MAOIs
Hypersensitivity to cetirizine or any component of the formulation
Avoid alcohol consumption due to increased risk of GI bleeding and liver damage. No specific food interactions; take with food or milk to reduce stomach upset. Caffeine may exacerbate pseudoephedrine's stimulant effects; limit caffeine intake.
No specific food interactions with Alaway ophthalmic solution. Take as directed, regardless of meals. Avoid rubbing eyes after application.
First trimester: Avoid due to potential increased risk of cardiac defects and gastroschisis from NSAIDs. Second trimester: Use with caution; ibuprofen may cause oligohydramnios and premature ductus arteriosus constriction. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. Phenylephrine: Limited human data; animal studies show fetal abnormalities at high doses; avoid in first trimester due to potential vascular disruption.
ALAWAY (azelastine) is classified as FDA Pregnancy Category C. In animal studies, azelastine administered orally during organogenesis produced fetal malformations (cleft palate, skeletal abnormalities) at maternally toxic doses (≥ 30 mg/kg/day in rats, 68 times the maximum recommended human intranasal dose). There are no adequate and well-controlled studies in pregnant women. First trimester: Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. Second and third trimesters: Limited data; avoid use unless necessary due to lack of safety evidence.
Ibuprofen: Excreted into breast milk in low amounts (M/P ratio ~0.07). Compatible with breastfeeding; minimal infant exposure. Phenylephrine: Not known if excreted in breast milk; M/P ratio unknown. Avoid due to potential for infant hypertension and irritability. Alternative decongestants preferred.
Azelastine is excreted in human breast milk; the milk-to-plasma ratio (M/P) is unknown. In a study of intranasal azelastine (2 sprays per nostril twice daily), the estimated daily infant dose via breast milk is 0.7% of the maternal dose, which is considered low. However, due to the potential for adverse effects in nursing infants (e.g., somnolence, irritability), caution is advised. Use only if clearly needed and benefit outweighs risk. Consider alternative therapies with more safety data.
Pharmacokinetic changes in pregnancy: Increased volume of distribution and clearance for ibuprofen may require higher doses, but avoid due to fetal risks. No standard dose adjustment recommended; use lowest effective dose for shortest duration. Phenylephrine: No specific dosing adjustments in pregnancy; avoid use due to limited safety data.
No specific dose adjustments are recommended for pregnancy. However, pharmacokinetic changes during pregnancy (e.g., increased plasma volume, altered hepatic metabolism) may reduce azelastine systemic exposure; the clinical significance is unknown. Use the lowest effective dose for the shortest duration. Maximum recommended intranasal dose: 2 sprays per nostril twice daily (total 548 mcg/day). Avoid exceeding this dose.
Advil Congestion Relief combines ibuprofen (NSAID) and pseudoephedrine (decongestant). Ibuprofen can cause nephrotoxicity; pseudoephedrine can elevate blood pressure and heart rate. Avoid in patients with uncontrolled hypertension, severe CAD, or MAOI use within 14 days. Use with caution in elderly due to increased risk of GI bleeding and CNS effects. Not recommended for children under 12 years.
Alaway (ketotifen fumarate ophthalmic solution) is used for prevention of itching associated with allergic conjunctivitis. It is a mast cell stabilizer with antihistamine properties. Onset of action occurs within minutes, but may require several days of use for full effect. Advise patients to avoid wearing contact lenses if eyes are red. Remove contacts before instillation and wait at least 10 minutes before reinserting.
Do not take more than directed; do not use with other products containing ibuprofen or other NSAIDs (e.g., naproxen, aspirin) due to increased risk of stomach bleeding.,Avoid alcohol while taking this medication to reduce the risk of stomach irritation and bleeding.,Pseudoephedrine may cause insomnia, nervousness, or dizziness; take the last dose at least 4-6 hours before bedtime.,Stop use and consult a doctor if symptoms persist after 5 days (fever >3 days), if new symptoms appear, or if you experience signs of stomach bleeding (black/bloody stools, vomit with blood/coffee-grounds).,Do not use if you have heart disease, high blood pressure, thyroid disease, diabetes, glaucoma, or difficulty urinating due to an enlarged prostate unless directed by a doctor.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before using this medication; wait at least 10 minutes after using drops before reinserting.,Use as directed, typically one drop in each affected eye twice daily, with at least 6-8 hours between doses.,Do not use while wearing contact lenses if eyes are red or irritated.,Temporary burning or stinging may occur upon instillation.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADVIL CONGESTION RELIEF vs ALAWAY, answered by our medical review team.
ADVIL CONGESTION RELIEF is a NSAID/Decongestant Combination that works by ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction. ALAWAY is a Ophthalmic Antihistamine that works by ALAWAY (cetirizine ophthalmic solution) is a selective histamine H1-receptor antagonist that inhibits histamine release from mast cells, reducing ocular itching and allergic conjunctivitis symptoms.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADVIL CONGESTION RELIEF and ALAWAY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADVIL CONGESTION RELIEF is: 1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.. The standard adult dose of ALAWAY is: 2 doses (each dose = 2 sprays) per nostril, repeated every 12 hours as needed. Each spray delivers 50 mg of sodium cromoglicate. Route: intranasal. Maximum: 2 doses per nostril per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADVIL CONGESTION RELIEF and ALAWAY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADVIL CONGESTION RELIEF is classified as Category C. First trimester: Avoid due to potential increased risk of cardiac defects and gastroschisis from NSAIDs. Second trimester: Use with caution; ibuprofen may cause oligohydramnios and. ALAWAY is classified as Category C. ALAWAY (azelastine) is classified as FDA Pregnancy Category C. In animal studies, azelastine administered orally during organogenesis produced fetal malformations (cleft palate, sk. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.